Author

A. Lercher

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3 Cancer Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 3 Approach:statistical model· 3 Assay:bulk RNA-seq· 2 Organism:mouse· 2 Organism:virus· 2 Research Focus:cancer & tumor microenvironment· 1 Assay:ChIP-seq· 1

Frequent Co-Authors

A. Bergthaler· 4 shared A. Popa· 3 shared B. Agerer· 3 shared C. Bock· 3 shared M. Smyth· 3 shared A. Zoufaly· 2 shared E. Pawelka· 2 shared H. Baazim· 2 shared

Activity by Year

2018-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersImmunology

A. Bergthaler

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Antiviral innate immune memory in alveolar macrophages following SARS-CoV-2 infection.

A. Lercher, J.-G. Cheong, C. Jiang, H.-H. Hoffmann, A. W. Ashbrook, Y. S. Yin, C. Quirk, E. J. DeGrace, L. Chiriboga, B. R. Rosenberg, S. Z. Josefowicz, C. M. Rice

This study shows that SARS-CoV-2 infection primes alveolar macrophages for enhanced antiviral responses against influenza A virus through epigenetic changes in IFN-I pathways.

bioRxiv · Nov 24, 2023 · PreprintImmunology

SARS-CoV-2 escapes CD8 T cell surveillance via mutations in MHC-I restricted epitopes

B. Agerer, M. Koblischke, V. Gudipati, M. Smyth, A. Popa, J.-W. Genger, L. Endler, D. M. Florian, V. Muehlgrabner, A. Lercher, P. Gattinger, R. Torralba-Gombau, T. Penz, I. Fae, S. Wenda, , A. Bergthaler

The paper identifies mutations in SARS-CoV-2 that reduce MHC-I binding and CD8+ T cell recognition, suggesting escape from immune surveillance.

bioRxiv · Dec 18, 2020 · PreprintImmunology

Mutational dynamics and transmission properties of SARS-CoV-2 superspreading events in Austria

A. Popa, J.-W. Genger, M. Nicholson, T. Penz, D. Schmid, S. W. Aberle, B. Agerer, A. Lercher, L. Endler, H. Colaco, M. Smyth, M. Schuster, M. Grau, F. Martinez Jimenez, O. Pich, , A. Bergthaler

This study analyzes SARS-CoV-2 superspreading events in Austria using genomic and epidemiological data to understand viral transmission and mutation dynamics.

Science Translational Medicine · Dec 9, 2020Peer-reviewedMicrobiology

Ifnar1 signaling breaks the hepatic urea cycle to regulate adaptive immunity

A. Lercher, A. Bhattacharya, A. M. Popa, M. Caldera, M. F. Schlapansky, H. Baazim, P. Majek, J. S. Brunner, L. J. Kosack, D. Vitko, T. Pinter, B. Guertl, D. Reil, U. Kalinke, K. L. Bennett, , A. Bergthaler

This study shows that IFN-I signaling in the liver disrupts the urea cycle, reducing arginine and increasing ornithine, which suppresses CD8 T cell responses and improves liver pathology during viral infection.

bioRxiv · Sep 10, 2019 · PreprintImmunology

The ERBB-STAT3 Axis Drives Tasmanian Devil Facial Tumor Disease

L. Kosack, B. Wingelhofer, A. Popa, B. Vilagos, A. Orlova, P. Majek, K. Parapatics, A. Lercher, B. Agerer, A. Ringler, J. Klughammer, M. Smyth, K. Khamina, H. Baazim, D. A. Rosa, , A. Bergthaler

This study identifies the ERBB-STAT3 axis as a driver of Tasmanian devil facial tumor disease and proposes a dual chemo-immunotherapeutic strategy.

bioRxiv · Apr 12, 2018Cancer Biology